{"id":"azd5851","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PI3K delta, AZD5851 disrupts the signaling pathways involved in B-cell activation and proliferation, which are key components in the development and progression of certain cancers. This mechanism of action is thought to contribute to the drug's therapeutic effects in treating various hematological malignancies.","oneSentence":"AZD5851 is a selective and potent inhibitor of the PI3K delta isoform.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:26.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"Relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT06084884","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-14","conditions":"Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT06194461","phase":"","title":"LTFU for All Cell and Gene Therapy Studies","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-17","conditions":"Hepatocellular Carcinoma, Prostate Cancer","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cell Therapy"],"phase":"phase_2","status":"active","brandName":"AZD5851","genericName":"AZD5851","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"AZD5851 is a selective and potent inhibitor of the PI3K delta isoform. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}